Latest updates for Ilgrx
Fresh curated links around ILGRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
- Inhibrx Biosciences: The Whole Story Rides On INBRX-106
- Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
Geron (GERN) Q2 2026 Earnings Call Transcript
RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.
Grifols (GRFS) Q2 2026 Earnings Call Transcript
CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.
Granules India gets First-To-File status for generic Lumryz tablets in US
This was Granules’ second Sole First-to-File ANDA, following its earlier approval for Amphetamine Extended-Release Tablets,
INVIVYD
INVIVYD Anonymous (not verified) Thu, 07/02/2026 - 06:06 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...
argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
INVIVYD
INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...
Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript
Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.
argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow
<
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Kedrion Biopharma extends U.S. agreement with Grifols
Kedrion Biopharma, a Fort Lee-based global biopharmaceutical company specializing in therapies for rare and serious diseases, announced an extension of its relationship with Grifol...
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
GRAIL (GRAL) Q2 2026 Earnings Call Transcript
Galleri volume jumped 35% year over year on physician adoption and digital partnerships.
argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?
<![CDATA[Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs]]>
ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
Argenx jumps on Phase 3 data for blockbuster Vyvgart
The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.